scFv(CEA)-OX40-CD3zeta CAR-T Lentivirus

The scFv(CEA)-OX40-CD3ζ CAR-T lentivirus is a high-quality research-grade lentiviral vector designed to deliver a second-generation chimeric antigen receptor (CAR) targeting carcinoembryonic antigen (CEA). Built on a self-inactivating (SIN) lentiviral backbone, this vector is designed to support stable genomic integration and persistent expression of the CAR gene cassette in transduced T cells, enabling reliable and sustained functional studies. Its modular structure combines a CEA-specific single-chain variable fragment (scFv) with an OX40 (CD134) co-stimulatory domain and a CD3ζ signaling module. This well-validated combination enhances T cell activation, persistence, and effector function while minimizing activation-induced T cell exhaustion. The lentiviral vector format allows for efficient gene delivery into both dividing and non-dividing cells, supporting efficient transduction of various primary T cell subsets.

This lentiviral product is suitable for a wide range of preclinical applications, focusing on CEA-positive malignancies, including colorectal cancer, pancreatic cancer, gastric cancer, and certain CEA-overexpressing lung cancers. It enables researchers to generate CEA-specific CAR-T cells for in vitro cytotoxicity studies, cytokine release profiling, degranulation assays, serial killing experiments, and phenotypic analysis, such as dynamic changes in memory differentiation and exhaustion markers under specific antigen pressure. In co-culture systems, it can be used to study T cell activation thresholds, affinity dependence, and the functional impact of OX40 co-stimulation relative to other co-stimulatory domains. The vector also facilitates the study of immunological synapse formation, CD3ζ downstream signaling pathway activation, and the interplay between co-stimulation and metabolic adaptation. In vivo, it can be used in appropriate animal models to assess tumor control, expansion and persistence kinetics, migration to tumor sites, and the impact of antigen density and heterogeneity on therapeutic durability.